Interested to invest in a #GeneTherapy for #FriedreichAtaxia ♿️ 🧬? We invite you to attend the 3rd edition of the webinar "Get to Know Biointaxis and BTX-101 (FRATAXAV®)". Register: lu.ma/s1f8ienn
🗓️ November 12
🕕 6 pm
⏳The campaign closes on 52 days
#StopAtaxia
🗣️ @AntoniMatilla, investigador de l'IGTP referent en Atàxia de Friedreich i cofundador de @biointaxis, projecte que ha rebut dos ajuts #CaixaImpulse d’Innovació en Salut:
"Amb els resultats que tenim fins ara, parlem d’una teràpia totalment curativa"
youtu.be/EnP8Bj53uwA?si=uQpT…
Spain leads in advanced therapy research within the EU, with over 930 clinical trials approved in 2024. 37.6% focused on oncology, 8.6% on immune disorders, and 7% on nervous system issues. Don't miss #BIOSPAIN2025 (7-9 Oct) in Barcelona to explore these innovations.
Biointaxis, spin-off del @GTRecerca, acaba de cerrar una ronda de financiación en Capital Cell para llevar su terapia génica FRATAXAV® a ensayos clínicos de Fase I con pacientes:
capitalcell.com/campaign/bio…
Our CSO & Co-Founder Ivelisse Sánchez was one of the 15 women innovators invited to attend #WebSummit 🚀 2024 in Lisbon, Europe’s biggest tech conference, with @EUREKA_NETWORK@EU_Commission.
Great opportunity to showcase our FRATAXAV® #GeneTherapy to cure #FriedreichAtaxia ♿️🧬
Remember to sign up to the webinar "Get to Know Biointaxis and How to Invest in FRATAXAV® Gene Therapy to Cure #FriedreichAtaxia": lu.ma/s1f8ienn
🗓️ Tuesday, Nov 12
🕔 5 pm
🗣️ Dr @AntoniMatilla, CEO & Co-Founder of Biointaxis, and Joan Mercadal, partner at NaraCapital
Interested to invest in a #GeneTherapy for #FriedreichAtaxia ♿️ 🧬? We invite you to attend the 3rd edition of the webinar "Get to Know Biointaxis and BTX-101 (FRATAXAV®)". Register: lu.ma/s1f8ienn
🗓️ November 12
🕕 6 pm
⏳The campaign closes on 52 days
#StopAtaxia